These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 20548045)

  • 21. Progression in multiple sclerosis: further evidence of an age dependent process.
    Koch M; Mostert J; Heersema D; De Keyser J
    J Neurol Sci; 2007 Apr; 255(1-2):35-41. PubMed ID: 17331540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.
    Kobelt G; Jönsson L; Miltenburger C; Jönsson B
    Int J Technol Assess Health Care; 2002; 18(1):127-38. PubMed ID: 11987436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Registry studies of long-term multiple sclerosis outcomes: description of key registries.
    Hurwitz BJ
    Neurology; 2011 Jan; 76(1 Suppl 1):S3-6. PubMed ID: 21205680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The natural history of multiple sclerosis: update 1998.
    Weinshenker BG
    Semin Neurol; 1998; 18(3):301-7. PubMed ID: 9817534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple sclerosis: epidemiology, genetics, classification, natural history, and clinical outcome measures.
    Wingerchuk DM; Weinshenker BG
    Neuroimaging Clin N Am; 2000 Nov; 10(4):611-24 ,vii. PubMed ID: 11359715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
    Glad SB; Nyland HI; Aarseth JH; Riise T; Myhr KM
    Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Azathioprine in multiple sclerosis: the cons.
    Silberberg DH
    Neurology; 1988 Jul; 38(7 Suppl 2):24-7. PubMed ID: 3290710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives.
    Bar-Zohar D; Agosta F; Goldstaub D; Filippi M
    Mult Scler; 2008 Jul; 14(6):719-27. PubMed ID: 18424478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modern multiple sclerosis treatment - what is approved, what is on the horizon.
    Pilz G; Wipfler P; Ladurner G; Kraus J
    Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early treatment trials with interferon beta in multiple sclerosis.
    Panitch HS
    Mult Scler; 1995; 1 Suppl 1():S17-21. PubMed ID: 9345392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The latest world standards in the diagnosis of multiple sclerosis].
    Obuchowska I; Mariak Z
    Klin Oczna; 2009; 111(1-3):70-4. PubMed ID: 19517851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early treatment.
    Comi G
    Neurol Sci; 2006 Mar; 27 Suppl 1():S8-12. PubMed ID: 16708191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The natural history of primary progressive MS in British Columbia, Canada.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2005 Dec; 65(12):1919-23. PubMed ID: 16380613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New treatment measurements for treatment effects on relapses and progression.
    Tintoré M; Sastre-Garriga J
    J Neurol Sci; 2008 Nov; 274(1-2):80-3. PubMed ID: 18822433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics of multiple sclerosis in Lebanon.
    Yamout B; Barada W; Tohme RA; Mehio-Sibai A; Khalifeh R; El-Hajj T
    J Neurol Sci; 2008 Jul; 270(1-2):88-93. PubMed ID: 18367208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving long-term follow-up studies of immunomodulatory therapies.
    Freedman MS
    Neurology; 2011 Jan; 76(1 Suppl 1):S35-8. PubMed ID: 21205681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Natural history of multiple sclerosis].
    Vukusic S; Confavreux C
    Presse Med; 2010 Mar; 39(3):359-62. PubMed ID: 20089380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple sclerosis.
    Zajicek J
    Handb Clin Neurol; 2013; 110():461-70. PubMed ID: 23312664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command.
    Freedman MS; Cohen B; Dhib-Jalbut S; Jeffery D; Reder AT; Sandberg-Wollheim M; Weinstock-Guttman B
    Curr Med Res Opin; 2009 Oct; 25(10):2459-70. PubMed ID: 19678753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.